Paclitaxel

CAS 33069-62-4 23 current records 27 historicalSmall Molecule

Who holds supplier records for Paclitaxel? 23 organisations hold a current record for Paclitaxel: an active US FDA Type II Drug Master File or a CEP. A further 27 organisations have only historical (inactive) DMF filings. 18 of them hold a valid EU Certificate of Suitability (19 holder entries on the EDQM register, listed below). Recorded organisation countries for current records: India (5), China (5), South Korea (2), Taiwan (1) and 4 other countries (4); not recorded for 6.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Paclitaxel: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/paclitaxel

Reading the evidence

  • 23 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 8 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Paclitaxel expires 12 Jul 2034. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (23)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Paclitaxel. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Paclitaxel sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (19)

Certificates of Suitability on the EDQM register for Paclitaxel, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 34 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
TAPI NL B.V. AmsterdamNL
CEP 2009-236 - Rev 07
Paclitaxel, Produced by semi-synthetic process
Sept 2026—
INTAS PHARMACEUTICALS LIMITED AhmedabadIN
CEP 2021-455 - Rev 01
Paclitaxel, Produced by a semi-synthetic process – Process II
Jul 2026—
HETERO LABS LIMITED HyderabadIN
CEP 2021-476 - Rev 01
Paclitaxel, Produced by a semi-synthetic process
May 2026—
SAMYANG BIOPHARM CORP. Seongnam-SiKR
CEP 2009-255 - Rev 03
Paclitaxel, Produced by fermentation
Apr 2026—
SCINOPHARM TAIWAN LTD. TainanTW
CEP 2015-278 - Rev 02
Paclitaxel, Produced by a semi-synthetic process, product code SPT 1308
Mar 2026—
WUXI TAXUS PHARMACEUTICAL CO. LTD. Wuxi CityCN
CEP 2024-437 - Rev 00
Paclitaxel
Nov 2025—
CHONGQING SINTAHO PHARMACEUTICAL CO., LTD. MaliuzuiCN
CEP 2022-006 - Rev 01
Paclitaxel, Produced by a semi-synthetic process
Oct 2025—
FRESENIUS KABI ONCOLOGY LIMITED KalyaniIN
CEP 2008-181 - Rev 12
Paclitaxel, Semi-synthetic process
Sept 2025—
MSN LABORATORIES PRIVATE LIMITED Kardanur VillageIN
CEP 2020-038 - Rev 02
Paclitaxel, Produced by a semi-synthetic process
Aug 2025Inspected Aug 2026
Slovakia
PHYTON BIOTECH LLC DeltaCA
CEP 2024-022 - Rev 01
Paclitaxel, Produced by fermentation - Site Agno
Jul 2025—
FUJIAN SOUTH PHARMACEUTICAL CO., LTD. SanmingCN
CEP 2019-110 - Rev 03
Paclitaxel, Produced by a semi-synthetic process
Jun 2025—
INDENA S.P.A. MilanIT
CEP 2019-346 - Rev 06
Paclitaxel, Produced by a semi-synthetic process – Process II
Feb 2025Inspected Jun 2026
Italy
Ningbo Green-Health Pharmaceutical Co., Ltd. NingboCN
CEP 2022-267 - Rev 00
Paclitaxel, produced by a semi-synthetic process
Oct 2024Inspected Jun 2024
Germany
WUHAN CALMLAND PHARMACEUTICALS CO., LTD. WuhanCN
CEP 2018-004 - Rev 02
Paclitaxel, produced by a semi-synthetic process
May 2024Inspected Apr 2026
Croatia
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2021-122 - Rev 02
Paclitaxel, Produced by a semi-synthetic process
Dec 2023—
INDENA S.P.A. MilanoIT
R1-CEP 2008-102 - Rev 03
Paclitaxel, produced by semi-synthetic process
Oct 2022—
POLYMED THERAPEUTICS, INC. HoustonUS
R1-CEP 2014-192 - Rev 00
Paclitaxel, Produced by a semi-synthetic process
Jun 2021—
CORDEN PHARMA BOULDER, INC. BoulderUS
R1-CEP 2009-126 - Rev 01
Paclitaxel, Produced by a semi-synthetic process
Feb 2021—
SERIPHARM S.A.S. Le MansFR
R1-CEP 2008-327 - Rev 00
Paclitaxel, Produced by a semi-synthetic process
Sept 2014—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (27)

Organisations whose Type II DMFs for Paclitaxel are no longer active. These show a past filing, not current supply.

Show all 27 historical records
  • India · Inactive DMF 25870 · filed Mar 2012
  • MAC CHEM PRODUCTS INDIA PVT LTD
    Inactive DMF 25843 · filed Mar 2012
  • JIANGSU YEW PHARMACEUTICAL CO LTD
    Inactive DMF 25759 · filed Jan 2012
  • SAI PHYTOCEUTICALS PVT LTD
    Inactive DMF 19660 · filed Jul 2006
  • BEIJING YI HE BIOTECH CO LTD
    Inactive DMF 19421 · filed May 2006
  • SHANGHAI JINSHAN BIOTECH CO LTD
    Inactive DMF 19293 · filed Mar 2006
  • CHONGQING UNITED PHARMACEUTICAL CO LTD
    Inactive DMF 19159, 16891 · filed Jan 2006
  • YUNNAN ZIYUN BIO TECH CO LTD
    Inactive DMF 17965 · filed Jan 2005
  • Inactive DMF 17650 · filed Sept 2004
  • PAXIS PHARMACEUTICALS
    Inactive DMF 17457 · filed Jun 2004
  • XIAN HIGH TECH INDUSTRIES CO LTD
    Inactive DMF 15961 · filed Apr 2002
  • TAIHUA NATURAL PLANT PHARMACEUTICAL CO LTD
    Inactive DMF 15382 · filed Apr 2001
  • SOUTHERN HERBALS LTD
    Inactive DMF 15200 · filed Nov 2000
  • HOSPIRA BOULDER INC
    Inactive DMF 15092 · filed Oct 2000
  • BIOXEL PHARMA INC
    Inactive DMF 14503 · filed Oct 1999
  • LD PHARMACEUTICAL
    Inactive DMF 14403 · filed Sept 1999
  • CHROMADEX INC
    Inactive DMF 14389 · filed Aug 1999
  • NAPRO BIOTHERAPEUTICS INC
    Inactive DMF 10504, 14350, 11841 · filed Aug 1999
  • KUNMING INSTITUTE OF BOTANY
    Inactive DMF 13980 · filed Feb 1999
  • HUIANG BIO CHEMICAL PRODUCT MANUFACTURE COMPANY LTD
    Inactive DMF 13826 · filed Nov 1998
  • CHONGQING UNIT MODERN TECHNOLOGY CO LTD
    Inactive DMF 13148 · filed Aug 1998
  • CSF BIOTECH
    Inactive DMF 13016 · filed Jun 1998
  • INDENA UK LTD
    Inactive DMF 12757 · filed Nov 1997
  • XECHEM INC
    Inactive DMF 12544 · filed Jun 1997
  • PHYTOGEN LIFE SCIENCES INC
    Inactive DMF 12130 · filed Aug 1996
  • GREEN SPRINGS BIOCHEMISTRY
    Inactive DMF 12069 · filed Jul 1996
  • HAUSER CHEMICAL RESEARCH INC
    Inactive DMF 9765, 8801, 11248 · filed Sept 1995

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (16 listed products contain Paclitaxel). The latest listed patent expires 12 Jul 2034. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Paclitaxel is a chemotherapy drug used to treat various types of cancer, including ovarian, breast, and non-small cell lung cancer. It works by interfering with the normal function of microtubules during cell division.

Chemical identity

IUPAC name
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Canonical SMILES
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
InChIKey
RCINICONZNJXQF-MZXODVADSA-N
Synonyms
Taxol, (-)-paclitaxel, abi 007 component paclitaxel, abi-007 component paclitaxel, abraxane component paclitaxel, bms-181339-01, capxol, cyclopax, dhp-107, ebetaxel, empac, endotag 1

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Microtubule Inhibitor
Physiologic effect
Microtubule Inhibition

Therapeutic areas

OncologyBreast CancerOvarian Cancer

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Paclitaxel?

23 organisations hold an active US FDA Type II Drug Master File or a CEP for Paclitaxel: Intas Pharmaceuticals Ltd. (India), SCINOPHARM TAIWAN LTD (Taiwan), APITORIA PHARMA PRIVATE LTD (India), Chongqing Sintaho Pharmaceutical Co., Ltd. (China), CORDEN PHARMA BOULDER INC, Fujian South Pharmaceutical Co. Ltd. (China), Hetero Labs Limited (India) and MSN Laboratories Private Limited (India), and 15 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Paclitaxel Drug Master Files are active?

Intas Pharmaceuticals Ltd. (DMF 36253, 26792), SCINOPHARM TAIWAN LTD (DMF 16676, 27567), APITORIA PHARMA PRIVATE LTD (DMF 36228), Chongqing Sintaho Pharmaceutical Co., Ltd. (DMF 36479), CORDEN PHARMA BOULDER INC (DMF 16439), Fujian South Pharmaceutical Co. Ltd. (DMF 25822, 23558), Hetero Labs Limited (DMF 26688) and MSN Laboratories Private Limited (DMF 32194) and 8 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Paclitaxel records mean?

27 organisations have only inactive Type II DMFs for Paclitaxel. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Paclitaxel have a European Certificate of Suitability?

Yes. 18 organisations hold a valid CEP for Paclitaxel on the EDQM register, including TAPI NL B.V. Amsterdam (NL), INTAS PHARMACEUTICALS LIMITED Ahmedabad (IN), HETERO LABS LIMITED Hyderabad (IN), SAMYANG BIOPHARM CORP. Seongnam-Si (KR), SCINOPHARM TAIWAN LTD. Tainan (TW) and WUXI TAXUS PHARMACEUTICAL CO. LTD. Wuxi City (CN) and 13 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Paclitaxel?

Yes. The latest patent listed for an approved US product containing Paclitaxel expires 12 Jul 2034, across 16 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Paclitaxel supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Paclitaxel?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.